Comparison of two ways of LCZ696 titration in heart failure patients

Registry ID

EUCTR2013-001835-33

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Novartis Pharma Services AG

Start date

2013-11-28

Completion date

2014-08-05

Last update

2026-08-16

Conditions

• Chronic heart failure

Summary

To assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction using conservative (reaching target dose over 6 weeks) and condensed (reaching target dose over 3 weeks) up-titration regimens.

Locations

• , , Slovakia
• , , Italy
• , , Spain
• , , Hungary
• , , Germany
• , , Finland
• , , UK
• , , Bulgarian Drug Agency

View on source registry